Abstract: The present invention relates to a composition comprising secreted extracellular vesicles (SEV) of cells expressing nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4(NFATC4), for use in the treatment of cancer or in the treatment or prevention of metastatic cancer. It further relates to in vitromethods for determining or predicting the therapeutic efficiency of a treatment with a composition comprising SEV of cells expressing NFATC4 in a cancer patient, based on the ability of the composition comprising SEV of cells expressing NFATC4 to induce an increase in TGF?1 expression level.
Type:
Grant
Filed:
March 29, 2017
Date of Patent:
October 26, 2021
Assignees:
Université de Paris, Institut National de la Sante et de la Recherce Medicale, Assistance Publique—Hopitaux de Paris